New Haven, Conn. — Yale Cancer Center (YCC) announces the publication of Molecular Determinants of Head and Neck Cancer, 2nd Edition, edited by Barbara Burtness, MD, medical oncologist at YCC and Erica Golemis, PhD, deputy chief science officer at Fox Chase Cancer Center.
“New insights into the biology of head and neck cancer, and the explosion of new trials with immunooncology agents, have dramatically changed treatment and research questions in the field of head and neck cancer,” said Burtness. “Our second edition of Molecular Determinants brings together chapters on the molecular etiology and immune microenvironment of head and neck cancer with discussions of advances in treatment, contributed by a distinguished group of authors, to provide a comprehensive update for this rapidly changing arena.”
This second edition informs readers of significant advances in the understanding of head and neck cancer biology and the new therapies that have become available, with a focus on novel drug targets to improve the outcomes of head and neck squamous cell carcinomas. Head and neck cancers arise in the oral cavity, pharynx, and larynx; approximately 600,000 new cases will be diagnosed worldwide in 2018.
The book specifically addresses the biology and treatment of different subtypes of HNSCC, including the rapidly growing class of human papillomavirus (HPV) – driven HNSCC.
For more information on Head and Neck Cancers, treatment programs and patient care at YCC visit: https://www.yalecancercenter.org/patient/programs/headneck/index.aspx
About Yale Cancer Center Yale Cancer Center (YCC) is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in southern New England. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.